Trusted Resources: News & Meetings
Latest announcements and gatherings
EMA Grants Orphan Drug Designation to JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPS I)
JCR Pharmaceuticals Co., Ltd. announced today that European Medicines Agency (EMA) has granted orphan drug designation to JR-171, an investigational drug for the treatment of mucoplysaccharidosis type I (MPS I, or Hurler, Hurler-Scheie and Scheie syndrome). JR-171 is a blood-brain-barrier (BBB)-penetrating form recombinant α-L-iduronidase that was developed using JCR’s proprietary J-Brain Cargo® BBB technology.
JR-171 received the orphan drug designation from the US Food Drug Administration (FDA) in February 2021. Currently JR-171 is undergoing a global Phase 1/2 clinical trial and the first patient in Japan was dosed in October, 2020 and in Brazil in March, 2021. The trial is also scheduled for enrolling patients in the US. The summary of this study is registered on clinicaltrials.gov.
BookmarkRelated Content
-
Surgical Management of an Aortic Root Dilatation in a Patient Suffering From Hunter SyndromeHunter syndrome is a rare disease leadin...
-
A Guide to Understanding MPS II (Hunter Syndrome)MPS II belongs to a group of inherited m...
-
Mucopolysaccharidoses (MPS) and Gene TherapyMucopolysaccharidoses (MPS) are a group ...
-
MPS 1: Where Are We NowDr. Sandra Kingma from the Centre for Ra...
-
The Beginning of the End of Allogeneic Transplantation for Hurler SyndromeHurler syndrome (mucopolysaccharidosis t...
-
Lysosomal Storage Disorders: Clinical, Biochemical and Molecular Profile From Rare Disease Centre, IndiaLysosomal storage disorders (LSDs) are a...
-
Mass General – Lysosomal Storage Disorders ProgramThe Lysosomal Storage Disorders Program ...
Powered by
